The guggul for chronic diseases: Ancient medicine, modern targets

Anticancer Research

Volumn 28, Issue 6 A, 2008, Pages 3647-3664

  Shishodia, Shishir ^a   Harikumar, Kuzhuvelil B ^b   Dass, Suchismita ^c   Ramawat, Krishan G ^c   Aggarwal, Bharat B ^b  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c M L SUKHADIA UNIVERSITY   (India)

Author keywords

Apoptosis; Cancer; Guggul; Guggulsterone; Hyperlipidemia; Inflammation; Review

Indexed keywords

ANDROGEN RECEPTOR; BCL2 RELATED PROTEIN A1; BFL A1 PROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CELL NUCLEUS RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYCLIN D1; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450; CYTOCHROME P450 2B; CYTOKINE; FARNESOID X RECEPTOR; FLICE INHIBITORY PROTEIN; GELATINASE B; GLUCOCORTICOID RECEPTOR; GUGGULSTERONE; GUM RESIN; HERBACEOUS AGENT; IAP 1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; RESIN; STAT3 PROTEIN; STEROID RECEPTOR; SURVIVIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; X LINKED INHIBITOR OF APOPTOSIS;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRITIS; ASPERGILLUS NIGER; BACTERIAL GENE; CELL ACTIVITY; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; CEPHALOSPORIUM; CEPHALOSPORIUM APHIDACOLA; CHRONIC DISEASE; CLINICAL TRIAL; COMMIPHORA; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; DRUG TARGETING; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION REGULATION; HEART PROTECTION; HUMAN; INFLAMMATORY DISEASE; LEUKODERMA; LIVER DISEASE; LIVER PROTECTION; METASTASIS; MITOSIS INHIBITION; MOLECULAR BIOLOGY; NEUROPROTECTION; NONHUMAN; OBESITY; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SEIZURE; SINUSITIS; TRADITIONAL MEDICINE; TUMOR PROMOTION; ULCER; URINARY TRACT INFECTION; VITILIGO;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHRONIC DISEASE; COMMIPHORA; HUMANS; NEOPLASMS; PLANT EXTRACTS; PLANT GUMS;

EID: 58149153271     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Satyavati GV: Guggulipid: a promising hypolipidaemic agent from gum guggul (Commiphora mukul). In: Economic and Medicinal Plant Research. Wagner H and Farnsworth NR (eds.). New York Academic Press, pp. 47-48, 1991.
2. Satyavati GV, Dwarakanath C and Tripathi SN: Experimental studies on the hypocholesterolemic effect of Commiphora mukul. Engl. (Guggul). Indian J Med Res 57: 1950-1962.1969.
3. Satyavati GV: Gum guggul (Commiphora mukul) - the success story of an ancient insight leading to a modern discovery. Indian J Med Res 87: 327-335, 1988.
4. Setia RC, Parthsarthy MV and Shah JJ: Development, histochemistry and ultrastructure of gum resin ducts in Commiphora mukul Engl. Ann Bot 41: 999-1004, 1977.
5. Bhatt JR, Nair MNB and Mohanram HY: Enhancement of oleogum resin production in Commiphora wightii by improved tapping technique. Curr Sci 58: 349-354, 1989.
6. Dev S: Chemistry of Commiphora mukul and development of a hypolipidemic drug. In: Studies in Natural Product Chemistry, Rehman A (ed.). Elsevier, Amsterdam, pp. 695-719, 1989.
7. Ramawat KG, Mathur M, Dass S and Suthar S: Guggulsterone: A potent hypolipidemic agent from Commiphora wightii-problems, perseverance and prospects. In: Bioactive Molecules and Medicinal Plants. Ramawat KG, Merillon JM (eds). Heidelberg, Springer, pp. 101-121, 2008.
8. Barve DM and Mehta AR: Clonal propagation of mature elite trees of Commiphora wightii. Plant Cell Tiss Org Cult 35: 237-244, 1993.
9. Kumar S, Suri SS, Sonie KC and Ramawat KG: Establishment of embryonic cultures and somatic embryogenesis in callus culture of guggul-Commiphora wightii (Arnott.) Bhandari. Indian J Exp Biol 41: 69-77, 2003.
10. Kumar S, Mathur M, Jain AK and Ramawat KG: Somatic embryo proliferation in Commiphora wightii and evidence for guggulsterone production in culture. Indian J Biotech 5: 212-215, 2006.
11. Kumar S, Sonie KC and Ramawat KG: Development of resin canals during somatic embryogenesis in callus cultures of Commiphora wightii. Indian J Biotech 3: 267-270, 2004.
12. Mathur M, Jain AK, Dass S and Ramawat KG: Optimization of guggulsterone production in callus cultures of Commiphora wightii (Arnott.) Bhandari. Indian J Biotech 6: 525-531, 2007.
13. Tanwar YS, Mathur M and Ramawat KG: Morphactin influences guggulsterone production in callus cultures of Commiphora wightii. Plant Growth Reg 51: 3-98, 2007.
14. Mathur M and Ramawat KG: Guggulsterone production in cell suspension cultures of Commiphora wightii grown in shake flasks and bioreactors. Biotech Letters 29: 979-982, 2007.
15. Gupta P, Shivanna KR and Mohanram HY: Apomixis and polyembryony in the guggul plant, Commiphora wightii. Ann Bot 78: 67-72, 1996.
16. Hanus LO, Rezanka T, Dembitsky VM and Moussaieff A: Myrrh-Commiphora chemistry. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 149: 3-27, 2005.
17. Nityanand S and Kapoor NK: Hypolipidaemic effect of ethyl acetate fraction of Commiphora mukul (guggul) in rats. Indian J Pharmacol 7: 106, 1975.
18. Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ and Moore DD: A natural product that lowers cholesterol as an antagonist ligand for FXR: Science 296: 1703-1706, 2002.
19. Benn WR and Dodson RL: The synthesis and stereochemistry of isomeric 16-hydroxy-17(20)-pregnenes. J Org Chem 29: 1142, 1964.
20. Sarkhel S, Yadava U, Prakas P, Jain GK, Singh S and Maulik PR: Guggulsterone E, a lipid-lowering agent from Commiphora mukul. Acta Cryallography E57: o285-o286, 2001.
21. Gupta VK, Bandhoria P, Gupta BD and Gupta KK: Crystal structure of guggulsterone Z. Crystallography Report 51: 265-270, 2006.
22. Bosely JA, Brown AL and Rogers JS: Food Composition for Reducing Insulin Resistance. USA, p. 737, 2004.
23. Pratap R, Pal R, Singh S, Shankar G, Nath C, Singh HK, Srivastava AK, Rastogi AK, Murthy RPS, Srivastava S, Asthana OP, Singh N and Nityanand S: Method of Treating a Cognitive Memory Dysfunction Using Guggulipid. USA, p. 896, 2005.
24. Atta-ur-Rahman, Choudhary MI, Shaheen F, Ashraf M and Jahan S: Microbial transformations of hypolipemic E-guggulsterone. J Nat Prod 61: 428-431, 1998.
25. Choudhary MI, Shah SA, Sami A, Ajaz A and Shaheen F: Fungal metabolites of (E)-guggulsterone and their antibacterial and radical-scavenging activities. Chem Biodivers 2: 516-524, 2005.
26. Seol W, Choi HS and Moore D: Isolation of proteins that interact specifically with the retinoid X receptor: Two novel orphan receptors. Mol Endocrinol 9: 72-85, 1995.
27. Owsley E and Chiang JY: Guggulsterone antagonizes farnesoid X receptor induction of bile salt export pump but activates pregnane X receptor to inhibit cholesterol 7alpha-hydroxylase gene. Biochem Biophys Res Commun 304: 191-195, 2003.
28. Zhang Y, Castellani LW, Sinal CJ, Gonzalez FJ and Edwards PA: Peroxisome proliferator-activated receptor-gamma coactivator lalpha (PGC-1alpha) regulates triglyceride metabolism by activation of the nuclear receptor FXR. Genes Dev 18: 157-169, 2004.
29. Stayrook KR, Bramlett KS, Savkur RS, Ficorilli J, Cook T, Christe ME, Michael LF and Burris TP: Regulation of carbohydrate metabolism by the farnesoid X receptor. Endocrinology 146: 984-991, 2005.
30. De Gottardi A, Dumonceau JM, Bruttin F, Vonlaufen A, Morard I, Spahr L, Rubbia-Brandt L, Frossard JL, Dinjens WN, Rabinovitch PS and Hadengue A: Expression of the bile acid receptor FXR in Barrett's esophagus and enhancement of apoptosis by guggulsterone in vitro. Mol Cancer 5: 48, 2006.
31. Wu J, Xia C, Meier J, Li S, Hu X and Lala DS: The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor. Mol Endocrinol 16: 1590-1597, 2002.
32. Ding X and Staudinger JL: The ratio of constitutive androstane receptor to pregnane X receptor determines the activity of guggulsterone against the Cyp2b10 promoter. J Pharmacol Exp Ther 314: 120-127, 2005.
33. Burris TP, Montrose C, Houck KA, Osborne HE, Bocchinfuso WP, Yaden BC, Cheng CC, Zink RW, Barr RJ, Hepler CD, Krishnan V, Bullock HA, Burris LL, Galvin RJ, Bramlett K and Stayrook KR: The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol Pharmacol 67: 948-954, 2005.
34. Fuchs M: Bile acid regulation of hepatic physiology: III. Regulation of bile acid synthesis: past progress and future challenges. Am J Physiol Gastrointest Liver Physiol 284: G551-557, 2003.
35. Kullak-Ublick GA, Stieger B and Meier PJ Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 126: 322-342, 2004.
36. Deng R, Yang D, Radke A, Yang J and Yan B: The hypolipidemic agent guggulsterone regulates the expression of human bile salt export pump: dominance of transactivation over farsenoid X receptor-mediated antagonism. J Pharmacol Exp Ther 320: 1153-1162, 2007.
37. Shishodia S and Aggarwal BB: Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J Biol Chem 279: 47148-47158, 2004.
38. Aggarwal BB: Nuclear factor-kappaB: The enemy within. Cancer Cell 6: 203-208, 2004.
39. Aggarwal BB, Takada Y, Shishodia S, Gutierrez AM, Oommen OV, Ichikawa H, Baba Y and Kumar A: Nuclear transcription factor NF-kappa B: role in biology and medicine. Indian J Exp Biol 42: 341-353, 2004.
40. Darnell JE Jr, Kerr IM and Stark GR: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421, 1994.
41. Ahn KS, Sethi G, Sung B, Goel A, Ralhan R and Aggarwal BB: Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through activation of a protein tyrosine phosphatase SHP-1. Cancer Res 68: 4406-4415, 2008.
42. Folkman J: Angiogenesis-dependent diseases. Semin Oncol 28: 536-542, 2001.
43. Xiao D and Singh SV: z-Guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, inhibits angiogenesis in vitro and in vivo. Mol Cancer Ther 7: 171-180, 2008.
44. Manjula N, Gayathri B, Vinaykumar KS, Shankernarayanan NP, Vishwakarma RA and Balakrishnan A: Inhibition of MAP kinases by crude extract and pure compound isolated from Commiphora mukul leads to down-regulation of TNF-alpha, IL-1beta and IL-2. Int Immunopharmacol 6: 122-132, 2006.
45. Ichikawa H and Aggarwal BB: Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand and by tumor cells by suppressing nuclear factor-kappaB activation. Clin Cancer Res 12: 662-668, 2006.
46. Lv N, Song MY, Kim EK, Park JW, Kwon KB and Park BH: Guggulsterone, a plant sterol, inhibits NF-kappaB activation and protects pancreatic beta cells from cytokine toxicity. Mol Cell Endocrinol 289(1-2): 49-59, 2008.
47. Francis JA, Raja SN and Nair MG: Bioactive terpenoids and guggulusteroids from Commiphora mukul gum resin of potential anti-inflammatory interest. Chem Biodivers 1: 1842-1853, 2004.
48. Kumar A, Dhawan S, Mukhopadhyay A and Aggarwal BB: Human immunodeficiency virus-1-tat induces matrix metalloproteinase-9 in monocytes through protein tyrosine phosphatase-mediated activation of nuclear transcription factor NF-kappaB. FEBS Lett 462: 140-144, 1999.
49. Meselhy MR: Inhibition of LPS-induced NO production by the oleogum resin of Commiphora wightii and its constituents. Phytochemistry 62: 213-218, 2003.
50. Shishodia S, Sethi G, Ahn KS and Aggarwal BB: Guggulsterone inhibits tumor cell proliferation, induces S-phase arrest, and promotes apoptosis through activation of c-Jun N-terminal kinase, suppression of Akt pathway, and down-regulation of antiapoptotic gene products. Biochem Pharmacol 74: 118-130, 2007.
51. 2-terminal kinase. Cancer Res 67: 7439-7449, 2007.
52. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M and Bartek J: Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57: 353-361, 1994.
53. Adelaide J, Monges G, Derderian C, Seitz JF and Birnbaum D: Oesophageal cancer and amplification of the human cyclin D gene CCND1/PRAD1. Br J Cancer 71: 64-68, 1995.
54. Caputi M, Groeger AM, Esposito V, Dean C, De Luca A, Pacilio C, Muller MR, Giordano GG, Baldi F, Wolner E and Giordano A: Prognostic role of cyclin D1 in lung cancer. Relationship to proliferating cell nuclear antigen. Am J Respir Cell Mol Biol 20: 746-750, 1999.
55. Nishida N, Fukuda Y, Komeda T, Kita R, Sando T, Furukawa M, Amenomori M, Shibagaki I, Nakao K, Ikenaga M and Ishizaki K: Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma. Cancer Res 54: 3107-3110, 1994.
56. Drobnjak M, Osman I, Scher HI, Fazzari M and Cordon-Cardo C: Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 6: 1891-1895, 2000.
57. Singh SV, Zeng Y, Xiao D, Vogel VG, Nelson JB, Dhir R and Tripathi YB: Caspase-dependent apoptosis induction by guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, in PC-3 human prostate cancer cells is mediated by Bax and Bak. Mol Cancer Ther 4: 1747-1754, 2005.
58. Samudio I, Konopleva M, Safe S, McQueen T and Andreeff M: Guggulsterones induce apoptosis and differentiation in acute myeloid leukemia: identification of isomer-specific antileukemic activities of the pregnadienedione structure. Mol Cancer Ther 4: 1982-1992, 2005.
59. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296: 1655-1657, 2002.
60. 2-terminal kinase activation, and defects in AP-1 transcriptional activity. Proc Natl Acad Sci USA 94: 3004-3009, 1997.
61. Nabekura T, Yamaki T, Ueno K and Kitagawa S: Effects of plant sterols on human multidrug transporters ABCB1 and ABCC1. Biochem Biophys Res Commun 369: 363-368, 2008.
62. Silva J, Dasgupta S, Wang G, Krishnamurthy K, Ritter E and Bieberich E: Lipids isolated from bone induce the migration of human breast cancer cells. J Lipid Res 47: 724-733, 2006.
63. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
64. Gujral ML, Sareen K, Tangri KK, Amma MK and Roy AK: Antiarthritic and anti-inflammatory activity of gum guggul (Balsamodendron mukul Hook). Indian J Physiol Pharmacol 4: 267-273, 1960.
65. Sharma JN: Comparison of the anti-inflammatory activity of Commiphora mukul (an indigenous drug) with those of phenylbutazone and ibuprofen in experimental arthritis induced by mycobacterial adjuvant. Arzneimittelforschung 27: 1455-1457, 1977.
66. Singh RB, Niaz MA and Ghosh S: Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drugs Ther 8: 659-664, 1994.
67. Singh K, Chander R and Kapoor NK: Guggulsterone, a potent hypolipidemic, prevents oxidation of low-density lipoprotein. Phytother Res 11: 291-294, 1997.
68. Wang X, Greilberger J, Ledinski G, Kager G, Paigen B and Jurgens G: The hypolipidemic natural product Commiphora mukul and its component guggulsterone inhibit oxidative modification of LDL. Atherosclerosis 172: 239-246, 2004.
69. Chander R, Khanna AK and Pratap R: Antioxidant activity of guggulsterone, the active principal of guggulipid from Commiphora mukul. J Med Arom Plant Sci 24: 370-374, 2002.
70. Chander R, Rizvi F, Khanna AK and Pratap R: Cardioprotective activity of synthetic guggulsterone (E and Zisomers) in isoproterenol induced myocardial ischemia in rats: A comparative study. Indian J Clin Biochem 18: 71-79, 2003.
71. Gupta A, Kapoor NK and Nityanand S: Mechanism of hypolipidemic action of standardized extract. Indian J Pharmacol 14: 1982.
72. Singh V, Kaul S, Chander R and Kapoor NK: Simultaneous low density lipoprotein receptor activity in liver membrane of guggulsterone treated rats. Pharmacology Research 22: 37-44, 1990.
73. Tripathi YB, Malhotra OP and Tripathi SN: Thyroid-stimulating action of Z-guggulsterone obtained from Commiphora mukul. Planta Med 50: 78-80, 1984.
74. Satyavati GV: Effect of an indigenous drug on disorders of lipid metabolism with special reference to atherosclerosis and obesity (Medoroga). M.D. Thesis (Department of Ayurveda). Banaras Hindu University, Varanasi, 1966.
75. Chander R, Khanna AK and Kapoor NK: Lipid-lowering activity of guggulsterone from Commiphora mukul in hyperlipidemic rats. Phytother Res 10: 508-511, 1996.
76. Cui J, Huang L, Zhao A, Lew JL, Yu J, Sahoo S, Meinke PT, Royo I, Pelaez F and Wright SD: Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J Biol Chem 278: 10214-10220, 2003.
77. Kumari K and Augusti KT: Lipid lowering effect of S-methyl cysteine sulfoxide from Allium cepa Linn. in high cholesterol diet fed rats. J Ethnopharmacol 109: 367-371, 2007.
78. Baldwa VS, Bhasin V, Ranka PC and Mathur KM: Effects of Commiphora mukul (guggul) in experimentally induced hyperlipemia and atherosclerosis. J Assoc Physicians India 29: 13-17, 1981.
79. Khanna DS, Agarwal OP, Gupta SK and Arora RB : A biochemical approach to anti-atherosclerotic action of Commiphora mukul: An Indian indigenous drug in Indian domestic pigs (Sus scrofa). Ind J Med Res 57: 900-906, 1969.
80. Dixit VP, Joshi S, Sinha R, Bharvava SK and Varma M: Hypolipidemic activity of guggal resin (Commiphora mukul) and garlic (Alium sativum Linn.) in dogs (Canis familiaris) and monkeys (Presbytis entellus entellus Dufresne). Biochem Exp Biol 16: 421-424, 1980.
81. Jialal I, Devaraj S and Venugopal SK: C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 44: 6-11, 2004.
82. Szapary PO, Wolfe ML, Bloedon LT, Cucchiara AJ, DerMarderosian AH, Cirigliano MD and Rader DJ: Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA 290: 765-772, 2003.
83. Kaul S and Kapoor NK: Reversal of changes of lipid peroxide, xanthine oxidase and superoxide dismutase by cardio-protective drugs in isoproterenol induced myocardial necrosis in rats. Indian J Exp Biol 27: 625-627, 1989.
84. Batra S, Srivastava S, Singh K, Chander R, Khanna AK and Bhaduri AP: Syntheses and biological evaluation of 3-substituted amino-1-aryl-6-hydroxy-hex- 2-ene-1-ones as antioxidant and hypolipidemic agents.Bioorg Med Chem 8: 2195-2209, 2000.
85. Singh RP, Singh R, Ram P and Batliwala PG: Use of Pushkar-Guggul, an indigenous antiischemic combination, in the management of ischemic heart disease. Int J Pharmacol 31: 147-160, 1993.
86. Miller AL: Botanical influences on cardiovascular disease. Altern Med Rev 3: 422-431, 1998.
87. Saxena G, Singh SP, Pal R, Singh S, Pratap R and Nath C: Guggulipid, an extract of Commiphora whighitii with lipid-lowering properties, has protective effects against streptozotocin-induced memory deficits in mice. Pharmacol Biochem Behav 86: 797-805, 2007.
88. Khanna D, Sethi G, Ahn KS, Pandey MK, Kunnumakkara AB, Sung B, Aggarwal A and Aggarwal BB: Natural products as a gold mine for arthritis treatment. Curr Opin Pharmacol 7: 344-351, 2007.
89. Singh BB, Mishra LC, Vinjamury SP, Aquilina N, Singh VJ and Shepard N: The effectiveness of Commiphora mukul for osteoarthritis of the knee: an outcomes study. Altern Ther Health Med 9: 74-79, 2003.
90. Al-Howiriny TA, Al-Sohaibani MO, Al-Said MS, Al-Yahya MA, El-Tahir KH and Rafatullah S: Hepatoprotective properties of Commiphora opobalsamum ("Balessan"), a traditional medicinal plant of Saudi Arabia. Drugs Exp Clin Res 30: 213-220, 2004.
91. Cheon JH, Kim JS, Kim JM, Kim N, Jung HC and Song IS: Plant sterol guggulsterone inhibits nuclear factor-kappaB signaling in intestinal epithelial cells by blocking IkappaB kinase and ameliorates acute murine colitis. Inflamm Bowel Dis 12: 1152-1161, 2006.
92. Tripathi SN, Gupta M, Sen SP and Udupa KN: Effect of a ketosteroid of Commifora mukul L. on hypercholesterolemia and hyperlipidemia induced by neomercazole and cholesterol mixture in chicks. Indian J Exp Biol 13: 15-18, 1975.
93. Thappa DM and Dogra J: Nodulocystic acne: oral guggulipid versus tetracycline. J Dermatol 21: 729-731, 1994.
94. Hamed MA and Hetta MH: Efficacy of Citrus reticulata and Mirazid in treatment of Schistosoma mansoni. Mem Inst Oswaldo Cruz 100: 771-778, 2005.
95. Massoud AM, El Ebiary FH and Abd El Salam: NF Effect of myrrh extract on the liver of normal and bilharzially infected mice. An ultrastructural study. J Egypt Soc Parasitol 34: 1-21, 2004.
96. Hassan M, El-Motaiem M, Afify H, Abaza B, El-Shafei M and Massoud AM: In vitro effect of Mirazid on Schistosoma mansoni worms. J Egypt Soc Parasitol 33: 999-1008, 2003.
97. Saeed MA and Sabir AW: Antibacterial activities of some constituents from oleo-gum-resin of Commiphora mukul. Fitoterapia 75: 204-208, 2004.
98. Dalvi SS, Nayak VK, Pohujani SM, Desai NK, Kshirsagar NA and Gupta KC: Effect of guggulipid on bioavailability of diltiazem and propranolol. J Assoc Physicians India 42: 454-455, 1994.
99. Brobst DE, Ding X, Creech KL, Goodwin B, Kelley B and Staudinger JL: Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. J Pharmacol Exp Ther 310: 528-535, 2004.
100. Kaul S and Kapoor NK: Cardiac sarcolemma enzymes and liver microsomal cytochrome P450 in isoproterenol-treated rats. Indian J Med Res 90: 62-68, 1989.
101. Rao RM, Khan ZA and Shah AH: Toxicity studies in mice of Commiphora molmol oleo-gum-resin. J Ethnopharmacol 76: 151-154, 2001.
102. Agarwal RC, Singh SP, Saran RK, Das SK, Sinha N, Asthana OP, Gupta PP, Nityanand S, Dhawan BN and Agarwal SS: Clinical trial of guggulipid - A new hypolipidemic agent of plant origin in primary hyperlipidemia. Indian J Med Res 84: 626-634, 1986.
103. Salavert M, Amarger S, Le Bouedec MC, Roger H, Souteyrand P and D'Incan M: Allergic contact dermatitis to guggul in a slimming cream. Contact Dermatitis 56: 286-287, 2007.
104. Kolonte A, Guillot B and Raison-Peyron N: Allergic contact dermatitis to guggul extract contained in an anticellulite gel-cream. Contact Dermatitis 54: 226-227, 2006.
105. Bianchi A, Cantu P, Firenzuoli F, Mazzanti G, Menniti-Ippolito F and Raschetti R: Rhabdomyolysis caused by Commiphora mukul, a natural lipid-lowering agent. Ann Pharmacother 38: 1222-1225, 2004.
106. Deng R: Therapeutic effects of guggul and its constituent guggulsterone: cardiovascular benefits. Cardiovasc Drug Rev 25: 375-390, 2007.
107. Kuppurajan K, Rajagopalan SS, Rao TK and Sitaraman R: Effect of guggul (Commiphora mukul-Engl.) on serum lipids in obese subjects. J Res India Med 8: 1-8, 1973.
108. Kuppurajan K, Rajagopalan SS, Rao TK and Sitaraman R: Effect of guggul (Commiphora mukul-Engl.) on serum lipids in obese, hypercholesterolemia and hyperlipemic cases. J Assoc Physicians India 26: 367-373, 1978.
109. Ghorai M, Mandal SC, Pal M, Pal SP and Saha BP: A comparative study on hypocholesterolaemic effect of allicin, whole germinated seeds of bengal gram and guggulipid of gum guggul. Phytother Res 14: 200-202, 2000.
110. Kotiyal JP, Bisht DB and Singh DS: Double cross-over trial of gum guggul (Commiphora mukul) fraction A in hypercholesterolemia. J Res India Med Yoga Hom 14: 11-16, 1979.
111. Verma SK and Bordia A: Effect of Commiphora mukul (gum guggulu) in patients of hyperlipidemia with special reference to HDL-cholesterol. Indian J Med Res 87: 356-360, 1988.
112. Nityanand S, Srivastava JS and Asthana OP: Clinical trials with guggulipid. A new hypolipidemic agent. J Assoc Physicians India 37: 323-328, 1989.
113. Ulbricht C, Basch E, Szapary P, Hammerness P, Axentsev S, Boon H, Kroll D, Garraway L, Vora M and Woods J: Guggul for hyperlipidemia: A review by the Natural Standard Research Collaboration. Complement Ther Med 13: 279-290, 2005.